Next generation sequencing system miseq I100 system with options for post-warranty service agreement and to purchase additional systems. EO 14398
Active Purchase Order Awarded
- Contract number
- 75F40126P00233
- Awardee
-
Illumina, Inc. UEI KMW3CRWNAAF3
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $53,443
Award facts
- Opportunity
-
- Next Generation Sequencing System Solicitation · 75F40126Q134622 · Posted Jul 28, 2026
- Contract value 31% obligated
-
- $53,442.90 Current, with exercised options
- $174,305.60 Potential, with all options
- Completion date 3% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 334516 Analytical Laboratory Instrument Manufacturing
- PSC
- 6630 Chemical Analysis Instruments
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Singapore
Award details come from SAM.gov/FPDS.
About this award
The Food and Drug Administration awarded a purchase order to Illumina, Inc. for a Next Generation Sequencing System MiSeq i100 with options for post-warranty service agreements and purchase of additional systems, valued at $174,305.60, on August 28, 2026.
Place of performance is Singapore. The system must deliver up to 25 gigabytes total output with 25 million reads per run, 500-base read length, and greater than 80 percent bases at Q30 quality score, supporting targeted DNA amplicon sequencing and microRNA sequencing applications for the FDA's Microbiology Surveillance Program. Equipment must be newly manufactured with OEM-certified parts, include unlimited software and firmware updates, and provide one scheduled on-site preventive maintenance visit annually with corrective maintenance available within three business days of service calls. Equipment delivery is required within 100 calendar days of award. The order includes one 12-month manufacturer's warranty and options for three one-year post-warranty maintenance service periods running through 2029–2030. Ultimate completion date is April 10, 2031. Pricing is firm fixed price. The order originated from an FDA solicitation posted July 28, 2026, with proposals due August 5, 2026, and award determination based on lowest priced technically acceptable offer.
Quick answers
Who was awarded contract 75F40126P00233?
75F40126P00233 was awarded to Illumina, Inc. by Food and Drug Administration (Department of Health and Human Services) on August 28, 2026.
How much is contract 75F40126P00233 worth?
The government has obligated $53,443 on 75F40126P00233. Its potential value, with all options, is $174,306.
Was contract 75F40126P00233 competed?
The extent of competition for 75F40126P00233 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award